Mannkind vs Sinovac Biotech
Mannkind and Sinovac Biotech are similar in size: $349m and $386m of revenue in their latest fiscal years. Mannkind grew faster (22.2% against 6.8%). Mannkind kept more of each dollar of sales as profit: a net margin of 1.7% against -15.5%.
| Latest fiscal year | MannkindMNKD, 2025 | Sinovac BiotechSVA, 2025 |
|---|---|---|
| Revenue | $349m | $386m |
| Revenue growth | 22.2% | 6.8% |
| Net income | $5.9m | −$59.7m |
| Operating margin | 11.1% | -127.0% |
| Net margin | 1.7% | -15.5% |
| Return on equity | — | -0.9% |
| Free cash flow | $13.7m | −$561m |
| Cash | $74.9m | $488m |
| Total debt | $361m | $495m |
| Debt to equity | — | 11.1% |
| Dividend per share | — | — |
| Dividend yield | — | 760.2% |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $1.16bn | $465m |
| Price vs our value range | — | — |
| Moat score | 20 (Weak) | — |
| Insider trades, 12 months | 1 buys, 14 sales | 0 buys, 0 sales |